Soluble Levels of Receptor for Advanced Glycation Endproducts (RAGE) and Progression of Atherosclerosis in Individuals Infected with Human Immunodeficiency Virus: ACTG NWCS 332 |
| |
| Authors: | Ann Danoff Michelle A. Kendall Judith S. Currier Theodoros Kelesidis Ann Marie Schmidt Judith A. Aberg |
| |
| Affiliation: | 1.Department of Medicine, VA Corporal Michael J Crecenz VA Medical Center, and Department of Medicine,Division of Endocrinology, Perelman School of Medicine,Philadelphia,USA;2.Center for Biostatistics in AIDS Research,Harvard T.H. Chan School of Public Health,Boston,USA;3.Department of Medicine, Division of Infectious Diseases,UCLA David Geffen School of Medicine,Los Angeles,USA;4.Department of Medicine, Division of Endocrinology,New York University School of Medicine,New York,USA;5.Department of Medicine, Division of Infectious Diseases,Icahn School of Medicine at Mount Sinai,New York,USA |
| |
| Abstract: | Identification of biomarkers and/or mediators of cardiovascular disease (CVD) associated with HIV infection would be of diagnostic and therapeutic value. As soluble receptor for advanced glycation endproducts (sRAGE) and endogenous secretory (esRAGE) have been implicated in vascular complications in other settings, we investigated whether either soluble form of RAGE was associated with changes in carotid intima-media thickness (CIMT) in HIV-infected patients and HIV-uninfected controls. We found no differences in sRAGE, esRAGE, or CIMT among groups at study entry, or in yearly rates of change in sRAGE, esRAGE, or CIMT by HIV-serostatus (all p?>?0.10). However, yearly rates of change in sRAGE (p?=?0.07) and esRAGE (p?p?=?0.06) were associated with increased odds of CIMT progression in HIV-infected individuals. Although esRAGE was not altered by HIV-serostatus (p?=?0.17), its inverse relationship with CIMT progression in HIV-infected patients suggests a possible role as a mediator of CVD in HIV-infected persons. |
| |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ |
|
